BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > Health > article

Samsung Bioepis demonstrates efficacy of first biosimilar for eye disease treatment

Lim Chang-won Reporter(cwlim34@ajunews.com) | Posted : May 18, 2020, 12:53 | Updated : May 18, 2020, 12:53
  • 트위터
  • 페이스북
  • 웨이보

An image captured from the website of Samsung Bioepisute [Courtesy of Samsung Bioepis]


SEOUL -- Samsung Bioepis, a U.S. and South Korean biopharmaceutical joint venture company, promised to seek a license for the marketing of SB11, a biosimilar candidate referencing Lucentis (ranibizumab), in the United States and Europe saying its efficacy has been demonstrated through final-stage clinical trials.

Ranibizumab, developed by Genentech and marketed by Novartis under the brand name Lucentis, is an anti-angiogenic that has been approved to treat the "wet" type of age-related macular degeneration, a common form of age-related vision loss.

From March 2018 to December 2019, Samsung Bioepis conducted clinical trials on 705 patients with neovascular age-related macular degeneration to compare and study clinical efficacy between SB11 and original medicines. The company said clinical equivalence with original medicines has been demonstrated.

Samsung Bioepis, a joint venture between Biogen, a U.S.-based pharmaceutical company, and Samsung BioLogics, a bio company affiliated with South Korea's largest Samsung Group, said it would apply for a license for SB11's sales in the U.S. and Europe as early as the end of this year. 

"Our first eye disease treatment is expected to provide excellent treatment benefits to patients," an unnamed Samsung Bioepis official was quoted as saying. SB11 is the company's sixth biosimilar and first ophthalmic disease treatment.

Samsung Bioepis has entered into a new commercialization agreement with Biogen for two biosimilar candidates, SB11 and SB15, in the U.S., Canada, Europe, Japan, and Australia. SB15, a biosimilar candidate referencing Eylea (aflibercept), is in pre-clinical development.

Samsung Bioepsis has been known for Imraldi, an adalimumab biosimilar referencing Humira. In 2019, the company won U.S. approval to sell its biosimilar referencing Enbrel (etanercept), one of the best-selling pharmaceutical products, that treats chronic diseases, including moderate to severe rheumatoid arthritis.
 

  • Lim Chang-won Reporter
  • email : cwlim34@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .Samsung Bioepis wins U.S. approval to sell cancer-treating biosimilar .
    Samsung Bioepis wins U.S. approval to sell cancer-treating b…
  • .Samsung Bioepis forges licensing deal with Chinese private equity firm .
    Samsung Bioepis forges licensing deal with Chinese private e…
  • .Samsung Bioepis allowed to go ahead with clinical trial in China for biosimilar candidate.
    Samsung Bioepis allowed to go ahead with clinical trial in C…
  • .Court suspends execution of action against Samsung Biologics.
    Court suspends execution of action against Samsung Biologics
  • .Prosecutors raid stock operators office in probe into Samsungs biosimilar arm.
    Prosecutors raid stock operator's office in probe into Samsu…

Real Time Photo News

  • .BTS agency posts record earnings in 2020 on brisk online activities and album sales .

    BTS agency posts record earnings in 2020 on brisk online activities and album sales

  • .[FOCUS] BTS agency leagues with Universal Music to launch new K-pop band in US music scene.

    [FOCUS] BTS agency leagues with Universal Music to launch new K-pop band in US music scene

  • .CJ ENM aims to become major visual content producer thru partnership with Epic Games .

    CJ ENM aims to become major visual content producer thru partnership with Epic Games

  • .​Solo singer Sunmi to come back with new album Tail.

    ​Solo singer Sunmi to come back with new album 'Tail'

  • .Big Hits live-streaming joint venture gains reinforcements from Universal Music, YG.

    Big Hit's live-streaming joint venture gains reinforcements from Universal Music, YG

Latest News

more+

  • Prime Minister Chung stresses importance of 'borderless communication channel' to minimize informati…
  • State hospital succeeds in inserting wireless pacemakers into hearts of bradyarrhythmia patients
  • LG Electronics' joint venture with Canada's Magna awaits approval by shareholders in March
  • Sajo Seafood to launch raw tuna menu delivery service
  • Researchers find new roundworm species near Dokdo
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view